Top intervention news from March: Low-risk TAVR, paclitaxel update and more

Cardiology Today’s Intervention compiled a list of the most-read articles posted on Healio.com/Intervention in March. This month, our readers were interested in developments from the American College of Cardiology Scientific Session including the success of transcatheter aortic valve replacement in low-risk patients, the FDA’s examination of paclitaxel-coated devices and much more.

Low-risk TAVR trials represent ‘historic moment’ in care of aortic stenosis

NEW ORLEANS — TAVR — already a mainstay of treatment for intermediate- and high-risk patients with severe aortic stenosis — may soon become the preferred therapy for low-risk patients as well.

Read more

AUGUSTUS: Dual therapy with apixaban, P2Y12 inhibitor safe in Afib patients post-ACS or PCI

NEW ORLEANS — New data from the AUGUSTUS trial provide insight on the appropriate antithrombotic regimen after ACS or PCI in patients with atrial fibrillation.

Read more

Preliminary FDA analysis finds paclitaxel-related mortality signal

An FDA official announced at a special meeting that the agency’s preliminary analysis of the possible link between paclitaxel-coated devices and mortality showed a signal of a link between the two, but no “smoking gun” to provide definitive proof or pinpoint a cause.

Read more

FDA recommends temporary halt to use of paclitaxel-coated devices in most patients with PAD

The FDA warned that using paclitaxel-coated products in the treatment of peripheral arterial disease in the femoropopliteal artery may increase mortality risk.

Read more

This month, our readers were interested in developments from the American College of Cardiology Scientific Session including the success of transcatheter aortic valve replacement in low-risk patients, the FDA’s examination of paclitaxel-coated devices and much more.
Source: Adobe Stock

Role of atherectomy in endovascular interventions up for debate

NEW ORLEANS — Atherectomy appears to have its place in practice, but experts remain somewhat divided over how judiciously the procedure should be used in endovascular interventions.

Read more

FDA approves device to close large-bore vascular punctures

The FDA announced that it recently approved a device to close large-bore puncture sites used to obtain vascular access in catheter-based procedures such as abdominal aortic aneurysm repair, TAVR and balloon aortic valvuloplasty.

Read more

Balloon-expandable TAVR safe in bicuspid aortic valves

NEW ORLEANS — Patients with bicuspid aortic valves who underwent TAVR with a balloon-expandable valve had similar rates of death and stroke at 1 year compared with patients with tricuspid aortic valves, according to new data highlighted at the American College of Cardiology Scientific Session.

Read more

Shorter DAPT duration after PCI improved outcomes at 1 year

NEW ORLEANS — Patients who took dual antiplatelet therapy after PCI for a shorter amount of time while continuing P2Y12 inhibitor monotherapy did not have an increased risk for MI, death or stroke compared with those who took standard therapy for 1 year, according to data from two studies presented at the American College of Cardiology Scientific Session.

Read more

BP-lowering effect of renal denervation persists at 6 months in RADIANCE-HTN SOLO

NEW ORLEANS — Endovascular ultrasound renal denervation resulted in BP reductions that were maintained at 6 months, with fewer prescriptions for antihypertension medications needed, compared with a sham procedure in patients with uncontrolled hypertension, researchers reported at the American College of Cardiology Scientific Session.

Read more

COAPT: Transcatheter mitral valve replacement brings health status improvements

NEW ORLEANS —Two substudies from the COAPT trial presented at the American College of Cardiology Scientific Session found that patients with moderate-to-severe or severe mitral regurgitation who had transcatheter mitral valve repair and guideline-directed medical therapy had improvements in health status as soon as 1 month.

Read more

Cardiology Today’s Intervention compiled a list of the most-read articles posted on Healio.com/Intervention in March. This month, our readers were interested in developments from the American College of Cardiology Scientific Session including the success of transcatheter aortic valve replacement in low-risk patients, the FDA’s examination of paclitaxel-coated devices and much more.

Low-risk TAVR trials represent ‘historic moment’ in care of aortic stenosis

NEW ORLEANS — TAVR — already a mainstay of treatment for intermediate- and high-risk patients with severe aortic stenosis — may soon become the preferred therapy for low-risk patients as well.

Read more

AUGUSTUS: Dual therapy with apixaban, P2Y12 inhibitor safe in Afib patients post-ACS or PCI

NEW ORLEANS — New data from the AUGUSTUS trial provide insight on the appropriate antithrombotic regimen after ACS or PCI in patients with atrial fibrillation.

Read more

Preliminary FDA analysis finds paclitaxel-related mortality signal

An FDA official announced at a special meeting that the agency’s preliminary analysis of the possible link between paclitaxel-coated devices and mortality showed a signal of a link between the two, but no “smoking gun” to provide definitive proof or pinpoint a cause.

Read more

FDA recommends temporary halt to use of paclitaxel-coated devices in most patients with PAD

The FDA warned that using paclitaxel-coated products in the treatment of peripheral arterial disease in the femoropopliteal artery may increase mortality risk.

Read more

This month, our readers were interested in developments from the American College of Cardiology Scientific Session including the success of transcatheter aortic valve replacement in low-risk patients, the FDA’s examination of paclitaxel-coated devices and much more.
Source: Adobe Stock

Role of atherectomy in endovascular interventions up for debate

NEW ORLEANS — Atherectomy appears to have its place in practice, but experts remain somewhat divided over how judiciously the procedure should be used in endovascular interventions.

Read more

FDA approves device to close large-bore vascular punctures

The FDA announced that it recently approved a device to close large-bore puncture sites used to obtain vascular access in catheter-based procedures such as abdominal aortic aneurysm repair, TAVR and balloon aortic valvuloplasty.

Read more

Balloon-expandable TAVR safe in bicuspid aortic valves

NEW ORLEANS — Patients with bicuspid aortic valves who underwent TAVR with a balloon-expandable valve had similar rates of death and stroke at 1 year compared with patients with tricuspid aortic valves, according to new data highlighted at the American College of Cardiology Scientific Session.

Read more

PAGE BREAK

Shorter DAPT duration after PCI improved outcomes at 1 year

NEW ORLEANS — Patients who took dual antiplatelet therapy after PCI for a shorter amount of time while continuing P2Y12 inhibitor monotherapy did not have an increased risk for MI, death or stroke compared with those who took standard therapy for 1 year, according to data from two studies presented at the American College of Cardiology Scientific Session.

Read more

BP-lowering effect of renal denervation persists at 6 months in RADIANCE-HTN SOLO

NEW ORLEANS — Endovascular ultrasound renal denervation resulted in BP reductions that were maintained at 6 months, with fewer prescriptions for antihypertension medications needed, compared with a sham procedure in patients with uncontrolled hypertension, researchers reported at the American College of Cardiology Scientific Session.

Read more

COAPT: Transcatheter mitral valve replacement brings health status improvements

NEW ORLEANS —Two substudies from the COAPT trial presented at the American College of Cardiology Scientific Session found that patients with moderate-to-severe or severe mitral regurgitation who had transcatheter mitral valve repair and guideline-directed medical therapy had improvements in health status as soon as 1 month.

Read more